News – Page 4 – LUMICKS

Blog posts

Dynamic single-molecule analysis reveals non-linear stiffening of mitotic chromosomes

In a recent study performed by Vrije Universiteit Amsterdam and the University of Copenhagen, researchers used LUMICKS’ u-Flux™ laminar flow microfluidics system together with optical tweezers and fluorescence microscopy – features combined in LUMICKS’ C-Trap® – to shed light on the structural organization of mitotic chromosomes. When preparing to undergo…

Chenlu Yu17 June 2022

“Avidity Enhancement” As New Strategy for Improving CAR T Therapy for AML

Press releases

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

The study details a novel strategy for better cancer treatment with CAR T cells for AML. "Avidity Enhancement", increasing cell-cell binding from both the tumor and CAR T cell side, led to a more effective eradication of tumors in mouse models of AML.

j.yeh24 May 2022

Blog posts

C-Trap^® studies reveal GroEL-ES protein folding acceleration mechanism

In a recent Science Advances publication, the group of Sander J. Tans from the AMOLF Institute, The Netherlands, demonstrate for the first time, at the single molecule level, how the molecular chaperone GroEL-ES modulates protein chain collapse and stimulates protein folding. Using LUMICKS’ C-Trap®, they were able to follow and visualize…

Chenlu Yu17 May 2022

Press releases

LUMICKS Appoints Andre Nel as Chief Financial Officer

We are very pleased to attract an experienced life sciences financial executive like Andre to LUMICKS at this pivotal point in our growth. His seasoned expertise across large, global life science companies, including Illumina and Pfizer, will be invaluable to us as we accelerate our growth worldwide.

j.yeh9 May 2022

Press releases

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.

j.yeh2 May 2022

Blog posts

New C-Trap^® installation at Radboud University to offer insights into chromatin organization

We are thrilled to announce the installation of a C-Trap® at the RIMLS-Science institute, Radboud University, The Netherlands, in the lab of Dr. Jorine Eeftens. The installed C-Trap combines dual-trap optical tweezers with super-resolution confocal microscopy, which will allow the team to perform and visualize single-molecule experiments with unprecedented detail to…

Chenlu Yu14 April 2022

Press releases

LUMICKS Strengthens its Innovative C-Trap^® Solution with Launch of New Lakeview Analysis Software Platform

With the release of the Lakeview Platform, we are bridging one of the biggest hurdles in our quest to democratize dynamic single-molecule instruments: straightforward data analysis that allows scientists to translate complex data sets to biologically relevant information

j.yeh4 April 2022

Blog posts

Exploring biomolecular condensate dynamics with the C-Trap^® reveals viscoelastic fluid behavior

In a recent article published in Nature Communications by the group of Huan-Xiang Zhou from the University of Illinois, Dr. Archishman Ghosh and co-workers provided insights into the dynamics of biomolecular condensates. Using LUMICKS’ C-Trap® with a dual-trap optical tweezer configuration they obtained direct evidence showing that phase-separated biopolymer condensates…

Chenlu Yu31 March 2022

Gosse Adema Professor, Radboud University Medical Centre Nijmegen

Press releases

New Study Highlights Cell Avidity’s Power to Provide Insights into the Robustness of T Cell Activation

New study by the team of Professor Gosse Adema demonstrates how cell avidity can be used to assess the effect of lead compounds on immune cells.

j.yeh22 March 2022

Press releases

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

Dr. Maher’s powerful research underscores the insights that our revolutionary technology can help researchers around the world discover, and help science better address core challenges in human health, particularly in designing potentially more effective immunotherapies to fight cancer.

j.yeh17 March 2022

Join our newsletter